Alumis (ALMS) Cash & Current Investments (2023 - 2025)
Alumis (ALMS) reported Cash & Current Investments of $89.8 million for Q4 2025, down 68.86% year-over-year from $288.3 million in Q4 2024, and down 76.24% quarter-over-quarter from $377.7 million in Q3 2025.
Alumis (ALMS) Cash & Current Investments (2023 - 2025) Analysis & Trends
Alumis (ALMS) has 3 years of Cash & Current Investments data on file, last reported at $89.8 million in Q4 2025.
- Cash & Current Investments for Q4 2025 came in at $89.8 million, down 68.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $89.8 million (down 68.86% YoY), and the FY2025 annual result was $89.8 million, down 68.86% from the prior year.
- Cash & Current Investments slipped to $89.8 million in Q4 2025 per ALMS's latest filing, from $377.7 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $377.7 million in Q3 2025 and troughed at $46.1 million in Q4 2023.
- A 3-year average of $175.1 million and a median of $152.1 million in 2025 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2024 and 2025: Cash & Current Investments soared 566.97% in 2024, then plunged 68.86% in 2025.
- A 3-year view of Cash & Current Investments shows it stood at $46.1 million in 2023, then jumped by 525.18% to $288.3 million in 2024, then plunged by 68.86% to $89.8 million in 2025.
- Business Quant data shows ALMS's Cash & Current Investments at $89.8 million in Q4 2025, $377.7 million in Q3 2025, and $152.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - | 89.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 89.75 Mn |
| Sep 30, 2025 | 377.72 Mn |
| Jun 30, 2025 | 152.12 Mn |
| Mar 31, 2025 | 208.75 Mn |
| Dec 31, 2024 | 288.26 Mn |
| Sep 30, 2024 | 361.87 Mn |
| Jun 30, 2024 | 155.22 Mn |
| Mar 31, 2024 | 112.07 Mn |
| Dec 31, 2023 | 46.11 Mn |
| Sep 30, 2023 | 54.26 Mn |
| Jun 30, 2023 | 79.77 Mn |